Altering fibrotic and rejection responses using biomaterial systems

从已建立的（例如缝合）到未来的（例如组织工程构建），聚合物已经发现了作为植入生物材料的各种应用。然而，它们的效用受到不可避免地发生的纤维组织积累和伴随的免疫反应的限制。拟议研究计划的长期目标是设计生物材料系统，以尽量减少纤维化和同种异体排斥反应。为了实现这些目标，我们在五年的赠款期限内有两个主要目标。1)使用模型生物材料，我们将提供候选抗纤维化药物，以减少局部瘢痕反应。2)通过从生物材料中递送关键化合物，我们将诱导耐受原性细胞，减少同种异体排斥反应。 生物活性“组合”装置的创建是相对较新的，并且主要由组织工程驱动。然而（尽管存在更复杂的监管问题），植入设备领域也将从积极引导反应远离纤维化和排斥反应的生物材料中受益匪浅。

From the established (e.g. stitches) to the futuristic (e.g. tissue-engineered constructs), polymers have found diverse applications as implanted biomaterials. Yet, their utility is limited by the accumulation of fibrous tissue that inevitably occurs and accompanying immune responses. The long-term objective of the proposed research program is to design biomaterial systems that minimise fibrosis and allogeneic rejection. In order to accomplish these goals, we have two major aims within the five year duration of the grant. 1) Using a model biomaterial, we will deliver candidate anti-fibrotic drugs to decrease local scarring responses. 2) By delivering key compounds from the biomaterial, we will induce tolerogenic cells that reduce allogeneic rejection. Creation of biologically active "combination" devices is relatively recent and has been driven primarily by tissue engineering. However (and despite more complex regulatory issues), the field of implanted devices will also benefit greatly from biomaterials that actively direct responses away from fibrosis and rejection.